Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps highlight key elements of the Medical Crossfire®: Expert Perspectives on the Emerging Role of CDK4/6 Inhibitors for the Management of Metastatic Breast Cancer online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Medical Crossfire®: Expert Perspectives on the Emerging Role of CDK4/6 Inhibitors for the Management of Metastatic Breast Cancer

Release Date: May 31, 2017
Expiration Date: May 31, 2018
Media: Internet - based

 

Activity Overview

This activity aims to update oncology professionals who participate in the treatment of patients with metastatic breast cancer by providing expert guidance, data interpretation, and clinical opinions on the importance and impact of a new class of therapy, CDK4/6 inhibitors.

  

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, gynecologic oncologists, and fellows who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain the mechanism of action of CDK 4/6 inhibition in the treatment of metastatic breast cancer
  • Discuss the role of current and emerging CDK4/6 inhibitor therapies in the treatment of metastatic breast cancer
  • Evaluate new and emerging clinical trial data that may change standards of care for patients with metastatic breast cancer
  • Identify strategies for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitor therapies in the management of metastatic breast cancer
  • Discuss whom will benefit from these agents and the importance of genetic testing


Faculty, Staff, and Planners' Disclosures

Chair:

Kimberly Blackwell, MD Professor of Medicine
Assistant Professor of Radiation Oncology
Duke University Medical Center
Durham, NC
 
 

Disclosure: Grant/Research Support: Pfizer, Novartis, Genentech, Celgene; Consultant: Advaxis, Bayer, Celgene, Coherus, Eisai, Eli Lilly, Genentech, GI Therapeutics, MacroGenics, Merck, Novartis, Pfizer, Pierian Biosciences, Puma Biotechnology, Sandoz, Syndax

Faculty:

Aditya Bardia, MD, MPH
Director of Precision Medicine, Center for Breast Oncology
Attending Physician, Massachusetts General Hospital
Assistant Professor, Harvard Medical School
Boston, MA

Disclosure: Grant/Research Support: Biotheranostics; Consultant: Novartis, Pfizer

Adam Brufsky, MD, PhD
Professor of Medicine, University of Pittsburgh School of Medicine
Associate Director, Clinical Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Chief, Division of Hematology/Oncology
University of Pittsburgh Department of Medicine
Pittsburgh, PA

Disclosure: Consultant: Pfizer, Lilly, Novartis

Harold Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Institute Physician, Dana-Farber Cancer Institute
Boston, MA

Disclosure: None

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By